Cytokinetics Q3 2026 Results: Net Loss of $190M, Loss Narrows
Cytokinetics filed its 10-Q for the period ending September 30, 2026, reporting 139,303,351 shares of common stock outstanding as of November 2, 2026. The company continues to advance its clinical pipeline, including aficamten and omecamtiv mecarbil, supported by various financing and royalty agreements with Royalty Pharma and Bayer.
- Key figure
- Net loss $190M